Assessing and Supporting Frail Patients with NDMM
Conversation centered around patient frailty, Dr. Cook and Dr. Pianko emphasize the importance of accurately assessing frailty and adjusting treatment plans accordingly.
ONL0119_2_SEG3
Video Player is loading.
EP: 1.Goals of Therapy and Treatment Options for Patients with Transplant-Ineligible NDMM
EP: 2.Clinical Implications from the MAIA and SWOG S0777 Studies
Now Viewing
EP: 3.Assessing and Supporting Frail Patients with NDMM
EP: 4.Implementing Real-world Evidence into Clinical Practice in NDMM
EP: 5.Optimizing Treatment Duration and Adverse Effect Management in Patients with NDMM
EP: 6.Addressing Unmet Needs and Disparities Across Patient Populations in Multiple Myeloma
EP: 7.Frontline Forum: Real-World Practice in Newly Diagnosed Multiple Myeloma
Recent Videos
Future of HER2-Directed Tumor-Agnostic Therapies
Influence of DESTINY-PanTumor02 Trials on Trastuzumab Deruxtecan Usage
Review of Current Landscape of HER2-Directed Tumor-Agnostic Therapies
Updates and Clinical Implications of DESTINY-Lung02 and DESTINY-Lung03 Trials
HER2 Key Differences and Current Approaches to Biomarker Testing
Introduction to HER2-Directed Tumor-Agnostic Approaches
Clinical Pearls Surrounding the Use of Bispecifics in R/R MM
R/R MM Treatment Landscape: Role of Bispecifics
Future Perspectives in R/R MM
Bispecifics in R/R MM: AE Management and Sequencing
Related Content
